Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Bearish
2
Neutral
8
Bullish
4
Bearish
27
Neutral
8
Bullish
11
Bearish
25
Neutral
0
Bullish
7
Discovery themes featuring this stock
Piramal Pharma Limited is a diversified global pharmaceutical and wellness company operating three core verticals: an integrated CDMO (Piramal Pharma Solutions), Complex Hospital Generics (Piramal Critical Care), and Consumer Healthcare (Piramal Consumer Healthcare), supported by 17 global facilities and a distribution network across 100+ countries, offering APIs, sterile injectables, ADCs, HPAPIs, formulations, and OTC consumer brands.
Q3 and 9M FY26 showed revenue softness with consolidated revenue down 3%/4% YoY and PAT turned negative (₹(136) Cr Q3; ₹(317) Cr 9M) mainly due to customer inventory destocking on a large on‑patent product, slower early‑stage CDMO order inflows and regulatory delays at the Digwal site, putting near‑term profitability under pressure.
CDMO is showing early recovery in RFPs and orders since October 2025 while PPL is pressing a US‑centric growth playbook: a US$90 million expansion at Lexington and Riverview and ~US$200 million cumulative US investment are targeted to capture onshoring demand and improve gross margins as North American sites scale.
CHG remains a cash‑generative, differentiated franchise with #1 positions: Sevoflurane value share at 47% in the US and intrathecal Baclofen at ~75% value share; the Kenalog® acquisition from BMS is intended to add a higher‑margin branded injectable without significant incremental manufacturing cost.
Piramal Consumer Healthcare continues outperformance: power brands contributed 51% of PCH sales with 30%/23% YoY growth in Q3/9M FY26, e‑commerce grew roughly 50% in 9M and accounts for about a quarter of PCH sales, highlighting a fast‑growing, asset‑light consumer vertical that supports overall group resilience.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
22,079 Cr
High Risk
—
26.5
—
2.7
241.00
148.30
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Piramal Pharma Ltd (PPLPHARMA) is currently trading at 162.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Piramal Pharma Limited is a diversified global pharmaceutical and wellness company operating three core verticals: an integrated CDMO (Piramal Pharma Solutions), Complex Hospital Generics (Piramal Critical Care), and Consumer Healthcare (Piramal Consumer Healthcare), supported by 17 global facilities and a distribution network across 100+ countries, offering APIs, sterile injectables, ADCs, HPAPIs, formulations, and OTC consumer brands. Q3 and 9M FY26 showed revenue softness with consolidated revenue down 3%/4% YoY and PAT turned negative (₹(136) Cr Q3; ₹(317) Cr 9M) mainly due to customer inventory destocking on a large on‑patent product, slower early‑stage CDMO order inflows and regulatory delays at the Digwal site, putting near‑term profitability under pressure. CDMO is showing early recovery in RFPs and orders since October 2025 while PPL is pressing a US‑centric growth playbook: a US$90 million expansion at Lexington and Riverview and ~US$200 million cumulative US investment are targeted to capture onshoring demand and improve gross margins as North American sites scale. CHG remains a cash‑generative, differentiated franchise with #1 positions: Sevoflurane value share at 47% in the US and intrathecal Baclofen at ~75% value share; the Kenalog® acquisition from BMS is intended to add a higher‑margin branded injectable without significant incremental manufacturing cost. Piramal Consumer Healthcare continues outperformance: power brands contributed 51% of PCH sales with 30%/23% YoY growth in Q3/9M FY26, e‑commerce grew roughly 50% in 9M and accounts for about a quarter of PCH sales, highlighting a fast‑growing, asset‑light consumer vertical that supports overall group resilience.
Over the past 52 weeks, Piramal Pharma Ltd has traded between a low of ₹148.30 and a high of ₹241.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Piramal Pharma Ltd has a market capitalization of approximately 22,078.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Piramal Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 22,078.81 Cr, Piramal Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Piramal Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Piramal Pharma Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore program aimed at making India a global hub for biopharma manufacturing, with a focus on biologics and biosimilars.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 | |
2025.00 | 57,267 Cr | 21.11 | 5.98 | 0.12 | 26.24 | 30.84 | 5.60 | |
1039.50 | 56,021 Cr | 66.55 | 11.66 | 0.12 | 14.23 | 15.05 | 8.94 | |
1480.15 | 37,818 Cr | 35.61 | 5.09 | 0.27 | 13.33 | 17.89 | 7.73 | |
166.10 | 22,079 Cr | — | 2.73 | 0.08 | -0.29 | 4.50 | -1.01 | |
773.70 | 15,258 Cr | 22.92 | 2.87 | 1.42 | 11.93 | 12.59 | 7.45 |
Regulatory Filing
Gujarat Pollution Control Board issued an interim revocation (13 Feb 2026) of closure directions for Piramal Pharma's Dahej site, authorizing immediate resumption of operations while the company works with GPCB to make the directions final.
Regulatory Filing
Gujarat Pollution Control Board granted an interim revocation of closure directions for Piramal Pharma's Dahej plant (13 Feb 2026), authorising immediate resumption of operations; company to work with GPCB to make directions final.
FDA Inspection
US FDA inspected Piramal Pharma's Digwal facility (9–13 Feb 2026) and issued a Form-483 with 4 observations classified as VAI (not related to data integrity); the company will submit a detailed response within timelines.
FDA Inspection
US FDA inspected Piramal Pharma's Digwal facility (9–13 Feb 2026) and issued a Form‑483 with four observations classified as Voluntary Action Indicated (not related to data integrity); company will respond within timelines.
